EGFR and breast cancer: Siddique et al. [43] investigated the in vitro and in vivo synergistic antiproliferative effects of oleocanthal and lapatinib (a dual EGFR and HER2 tyrosine kinase inhibitor approved for treatment of advanced HER2-positive breast cancer) in BT-474 and SK-BR-3 human breast cancer cell lines and in an orthotopic xenograft tumor model of BT-474 cells in nude mice.